Metronidazole / Miconazole Nitrate Suppliers & Bulk Manufacturers

Available Forms: Vaginal suppository

Available Strengths: 500 mg + 100 mg / 750mg+200mg

Reference Brands: Invel (USA/EU), Trimic, Inserdin, Ovulomix (LATAM)

Category: Anti-fungal

METRONIDAZOLE+MICONAZOLE is a combination medicine used to treat vaginal infections. Vaginal infection is the infection of the vagina and vulva (tissue at the opening of the vagina), which occurs due to the overgrowth of bacteria and fungi. Vaginal infection can cause inflammation, itchiness, thick discharge, change in colour of the discharge, burning sensation or pain during urination, vaginal bleeding or spotting, and pain during intercourse. Metronidazole / Miconazole nitrate is available in Vaginal suppository and strengths such as 500 mg + 100 mg / 750mg+200mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Metronidazole / Miconazole nitrate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Metronidazole / Miconazole nitrate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Metronidazole and miconazole nitrate combination is widely used for the treatment of mixed vaginal infections, including bacterial vaginosis, candidiasis, and other forms of vaginitis caused by bacteria, fungi, and protozoa. This dual-action therapy combines metronidazole, an antimicrobial agent effective against anaerobic bacteria and protozoa, with miconazole nitrate, an antifungal agent that targets Candida species. Together, these active ingredients provide broad-spectrum coverage for common vaginal pathogens.

Clinical studies have shown significant improvement in both symptoms and clinical signs of vaginitis following treatment with this combination therapy. The overall clinical cure rate has been reported to be approximately 87.7%. Laboratory evaluations also demonstrate strong effectiveness, with cure rates of about 81.8% based on microscopy and 73.9% according to Candida albicans culture results. In cases of bacterial vaginosis, the treatment achieved a cure rate of around 75%, while cultures of Gardnerella vaginalis became negative in approximately 63.6% of treated patients.

The medication is generally well tolerated and provides an effective therapeutic option for managing mixed vaginal infections, helping restore the normal vaginal microbial balance and relieve symptoms such as discharge, itching, and irritation.